Search Results

VGXI, Inc. has entered into a strategic partnership with Sutro Biopharma, Inc. to support clinical production of luveltamab tazevibulin, abbreviated as “luvelta”, a novel Folate Receptor-α -targeting antibody-drug conjugate with the potential to address the unmet need in several FRα-expressing cancers.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024.

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”) and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer (NSCLC).

Regen BioPharma, Inc., a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on May 9, 2024.

Avirmax Biopharma, Inc. is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration.

There are multiple ways biopharmas create inclusive workplaces for LGBTQ+ employees, and they go beyond employee resource groups and benefits.

Benitec Biopharma Inc. today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024.

Immix Biopharma, Inc. today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.

ABVC BioPharma, Inc and Oncology/Hematology, announced today that the Company’s subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry.